Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum The Medipattern Corporation V.MKI

TSXV:MKI - Post Discussion

The Medipattern Corporation > 63% increase over previous Q
View:
Post by goofenoff on Oct 10, 2012 9:10am

63% increase over previous Q

Medipattern Volume Significantly Increases Over Last Quarter (ccnm)

TORONTO, ONTARIO--(Marketwire - Oct. 10, 2012) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), announced today that Visualize:Vascular™ was used to render 3D on 1,243 carotid artery exams during the quarter starting in July 2012 and ending in September 2012, a 63% increase over the prior quarter. Medipattern focuses on the development and commercialization of healthcare solutions that positively impact people's lives through the prevention of disease and analysis of medical images and data. Visualize:Vascular™ is the fee-per-use solution for 3D rendering of carotid arteries. The company reports it is continuing to expand its customer base to 46 customers who have a combined total of 272 sites or mobile units.

The company's iaHealth Business Unit has been focusing its sales effort toward the mobile segment. Mobile ultrasound is an increasingly attractive alternative to in-house services. A vascular ultrasound service company provides skilled technologists and ultrasound equipment bundled as a service to physician offices, outpatient centers, specialty care centers and convalescent care facilities. Visualize:Vascular is now part of the product offering for several ultrasound service providers: AR Testing in New York, Mobile Diagnostics and Testing (MD&T) in New Jersey, Prime Diagnostics in New York, and Rapid Access Medical in New York.

"Mobile Service Providers are known as Independent Diagnostic Test Facilities (IDTF). To add a new procedure, such as 3D rendering, to our offering we have to receive state approval for all of the states in which we operate. We just received clearance from the State of New York in August," commented Scott Sokul president of AR Testing. "The benefits of using 3D are very rewarding. Visualize's 3D results give us more help to better understand luminal integrity than conventional Doppler ultrasound. 3D gives you more detail than 2D - it is as simple as that."

"Medipattern is pleased that Visualize has been shown to make a positive impact for the patients in the practices which mobile ultrasound providers serve. Mobile ultrasound providers once approved can add significantly to our total volume of business, with customers ranging from 500 to 5,000 carotid scans per month," commented Jeff Collins, CEO of Medipattern. "Our mobile customers are beginning to receive their approvals and should start to add into our total scan volume in the coming quarters and can make a significant impact on Medipattern's volume. We welcome them to our customer family."

About the Medipattern Corporation:

Medipattern® is an award-winning leader in the development and commercialization of healthcare solutions that positively impact people's lives through the prevention of disease and analysis of medical images and data. Medipattern's Knowledge-based Informatics (MKI) platform enables delivery of these streamlined solutions. Medipattern mHealth uses patented prevention technologies to engage, coach and monitor people in achieving their personalized goals. Medipattern iaHealth uses patented pattern recognition technology to analyze medical data to aid medical practitioners in the assessment of disease and critical anatomy. For more information, please visit the Company's website: www.medipattern.com

.

Medipattern® and B-CAD® are registered trademarks of The Medipattern Corporation. Visualize:Vascular™ is a registered trademark of Medipattern and SMARTCOACH™ is a trademark of MYTRAK Health Systems and will be under temporary license to Medipattern while the company reviews branding.

Comment by jtmenard on Oct 10, 2012 9:36am
It's a good news:   Medipattern is pleased that Visualize has been shown to make a positive impact for the patients in the practices which mobile ultrasound providers serve. Mobile ultrasound providers once approved can add significantly to our total volume of business, with customers ranging from 500 to 5,000 carotid scans per month," commented Jeff Collins, CEO of Medipattern ...more  
Comment by segltech on Oct 10, 2012 10:20am
Scans by QTR - 355,,,723   1,243. This is not the kind of growth Jeff Collins indicated when he set the time facture for being cash positive. I have to think that they have now added the mobile segment of this business to help speed up the process. The addition of the Smartcoach business should greatly add to the sales. I believe that they went into the Smartcoach ...more  
Comment by fjrmoto on Oct 10, 2012 2:46pm
q1-q3 scans almost quadrupled from a standing start....just for fun use the same growth rate multiple for the next 12 quarters.............good hold, great hold if momentum builds and growth explodes. glta
Comment by segltech on Oct 10, 2012 4:31pm
I think the income from the smartcoach business (product sales and services) will be much greater than the scanning business in the current and next Qtr.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities